SecurityADBE / Adobe Systems, Inc. (00724F101)
IndustryPrepackaged Software
Common Stock Shares Outstanding490,435,000 shares (as of 2018-06-01)
Total Insiders32
Total Directors19
Total Officers13

Stock Insider Trading (from SEC Form 4)

ADBE / Adobe Systems, Inc. Insider Trades

Adobe Systems, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ADBE / Adobe Systems, Inc. insiders include ValueAct Holdings, L.P., Banse Amy, Morris Donna, Rencher Bradley, CANNON MICHAEL R, SEDGEWICK ROBERT, Rao Dana, DILLON MICHAEL A, Parasnis Abhay, Desmond Laura, Barlow Kelly J, BARNHOLT EDWARD W, THOMPSON MATTHEW, Lewnes Ann, GARRETT MARK, ValueAct Capital Master Fund, L.P., BURGESS ROBERT K, ValueAct Capital Management, L.P., Belsky Scott, and CALDERONI FRANK, ValueAct Holdings GP, LLC, ROSENSWEIG DANIEL, LAMKIN BRYAN, ROWLEY RICHARD, Ricks David A NARAYEN SHANTANU, Murphy John Francis, ValueAct Capital Management, LLC, WARNOCK JOHN E, GESCHKE CHARLES M, VA Partners I, LLC, DALEY JAMES E, .

Insider Roster

Insider Dir Off 10% Shares Owned
Lewnes Ann EVP, Chief Marketing Officer
X 61,498
Rencher Bradley EVP & GM, Experience Cloud
X 80,071
Rao Dana EVP, Gen. Counsel & Secretary
X 18,311
Parasnis Abhay EVP & CTO
X 31,376
GESCHKE CHARLES M Director
X 152,059
Banse Amy Director
X 33,488
Ricks David A Director
X 0
CALDERONI FRANK Director
X 25,887
BURGESS ROBERT K Director
X 16,030
BARNHOLT EDWARD W Director
X 42,960
ROSENSWEIG DANIEL Director
X 13,104
WARNOCK JOHN E Director
X 470,344
Desmond Laura Director
X 25,887
DALEY JAMES E Director
X 32,922
Murphy John Francis EVP and CFO
X
DILLON MICHAEL A EVP, Gen. Counsel & Secretary
X 50,614
GARRETT MARK EVP, CFO & Asst. Secretary
X 50,000
LAMKIN BRYAN EVP & GM, Digital Media
X 60,154
THOMPSON MATTHEW EVP WW Field Operations
X 50,000
Morris Donna EVP, Cust. & Emp. Experience
X 65,083
Belsky Scott EVP, Chief Product Officer
X
NARAYEN SHANTANU Chairman, President and CEO, Director
X X 299,514
ROWLEY RICHARD VP, Corp. Controller & CAO
X
ValueAct Capital Management, L.P. Director
ValueAct Capital Management, LLC Director
ValueAct Capital Master Fund, L.P. Director
ValueAct Holdings GP, LLC Director
ValueAct Holdings, L.P. Director
Barlow Kelly J Director
VA Partners I, LLC Director
X
SEDGEWICK ROBERT Director
X
CANNON MICHAEL R Director
X
ValueAct Holdings GP, LLC Director
ValueAct Holdings, L.P. Director
ValueAct Capital Master Fund, L.P. Director
VA Partners I, LLC Director
ValueAct Capital Management, L.P. Director
ValueAct Capital Management, LLC Director
X
ValueAct Holdings, L.P. Director
ValueAct Holdings GP, LLC Director
ValueAct Capital Management, LLC Director
ValueAct Capital Management, L.P. Director
VA Partners I, LLC Director
ValueAct Capital Master Fund, L.P. Director
X
ValueAct Capital Management, LLC Director
ValueAct Capital Management, L.P. Director
ValueAct Holdings GP, LLC Director
ValueAct Holdings, L.P. Director
ValueAct Capital Master Fund, L.P. Director
VA Partners I, LLC Director
X
ValueAct Capital Master Fund, L.P. Director
VA Partners I, LLC Director
ValueAct Capital Management, L.P. Director
ValueAct Holdings GP, LLC Director
ValueAct Capital Management, LLC Director
ValueAct Holdings, L.P. Director
X
VA Partners I, LLC Director
ValueAct Holdings GP, LLC Director
ValueAct Capital Management, LLC Director
ValueAct Capital Management, L.P. Director
Barlow Kelly J Director
ValueAct Holdings, L.P. Director
ValueAct Capital Master Fund, L.P. Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-15 4 Lewnes Ann S X D 253.80 -2,939 61,498 15,608,192
2018-07-25 4 Rencher Bradley S D 262.3448 -15,000 80,071 21,006,210
2018-07-24 4 Parasnis Abhay S D 260.0055 -10,500 31,376 8,157,933
2018-07-20 4 Parasnis Abhay F D 257.54 -20,699 41,876
2018-07-20 4 Parasnis Abhay M D 41,750 62,575
2018-07-02 4 Rao Dana F D 243.26 -1,353 18,311
2018-07-02 4 Rao Dana M D 2,730 19,664
2018-07-18 4 Lewnes Ann S X D 257.86 -2,940 64,437 16,615,725
2018-06-20 4 Lewnes Ann S X D 253.50 -2,945 67,377 17,080,070
2018-06-18 4 GESCHKE CHARLES M By Family Trust S I 255.1925 -6,000 152,059 38,804,316
2018-05-16 4 Lewnes Ann S X D 236.59 -2,942 70,322 16,637,482
2018-04-20 4 GESCHKE CHARLES M By Family Trust S I 225.0844 -6,000 158,059 35,576,615
2018-04-20 4 GESCHKE CHARLES M By Family Trust S I 223.9118 -10,000 164,059 36,734,746
2018-04-18 4 Lewnes Ann S X D 231.70 -2,937 73,264 16,975,269
2018-04-11 4 DALEY JAMES E M D 2,035 32,922
2018-04-11 4 Desmond Laura M D 2,035 25,887
2018-04-11 4 GESCHKE CHARLES M By Family Trust M I 2,035 174,059
2018-04-11 4 WARNOCK JOHN E by trust S I 223.7721 -3,000 470,344 105,249,865
2018-04-11 4 WARNOCK JOHN E by trust M I 2,035 473,344
2018-04-11 4 ROSENSWEIG DANIEL M D 2,035 13,104
2018-04-11 4 BARNHOLT EDWARD W M D 2,035 42,960
2018-04-11 4 BURGESS ROBERT K by trust M I 2,035 16,030
2018-04-11 4 CALDERONI FRANK M D 2,035 25,887
2018-04-11 4 Banse Amy M D 2,035 33,488
2018-03-29 4 WARNOCK JOHN E by trust S I 218.0016 -5,000 471,309 102,746,116
2018-03-29 4 WARNOCK JOHN E by trust S I 216.0592 -6,000 476,309 102,910,941
2018-03-29 4 WARNOCK JOHN E by trust S I 215 -3,000 482,309 103,696,435
2018-03-22 4 Lewnes Ann S X D 223.86 -2,940 76,201 17,058,356
2018-03-20 4 Murphy John Francis F D 229.75 -2,288 3,555
2018-03-20 4 Murphy John Francis M D 5,750 5,843
2018-03-20 4 WARNOCK JOHN E by trust S I 229.5594 -2,500 485,309 111,407,243
2018-03-19 4 WARNOCK JOHN E by trust S I 220.3298 -2,500 487,809 107,478,859
2018-02-06 4 GARRETT MARK S X D 188.2518 -16,720 50,000 9,412,590
2018-02-06 4 GARRETT MARK S X D 187.988 -24,468 66,720 12,542,559
2018-02-06 4 GARRETT MARK S X D 186.5531 -3,900 91,188 17,011,404
2018-02-06 4 GARRETT MARK S X D 185.6946 -2,280 95,088 17,657,328
2018-02-06 4 GARRETT MARK S X D 184.2585 -7,120 97,368 17,940,882
2018-02-05 4 DILLON MICHAEL A S X D 194.8574 -7,400 50,614 9,862,512
2018-02-05 4 DILLON MICHAEL A S X D 194.2168 -5,958 58,014 11,267,293
2018-02-05 4 DILLON MICHAEL A S X D 193.3675 -4,721 63,972 12,370,106
2018-01-31 4 DILLON MICHAEL A S X D 197.13 -6,376 68,693 13,541,451
2018-01-31 4 LAMKIN BRYAN S D 199.0785 -30,000 60,154 11,975,368
2018-01-26 4 THOMPSON MATTHEW Trust S I 200.0765 -50,775 50,000 10,003,825
2018-01-25 4 NARAYEN SHANTANU by trust S I 198.6211 -57,352 299,514 59,489,800
2018-01-25 4 NARAYEN SHANTANU by trust S I 197.6312 -92,539 356,866 70,527,856
2018-01-25 4 NARAYEN SHANTANU by trust S I 196.7502 -15,132 449,405 88,420,524
2018-01-24 4 NARAYEN SHANTANU by trust F I 197.78 -14,044 464,537
2018-01-24 4 NARAYEN SHANTANU by trust M I 28,327 478,581
2018-01-24 4 NARAYEN SHANTANU by trust F I 197.78 -16,190 450,254
2018-01-24 4 NARAYEN SHANTANU by trust M I 32,655 466,444
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Shopify: Competition Knocking On The Expensive Door

21h seekingalpha
Adobe Systems entered the sector with the purchase of Magento to compete for the e-commerce platform of large brands. (9-0)

The One-Week Pre-Earnings Momentum Pattern With Options In Adobe Systems

2018-08-19 seekingalpha
This phenomenon is one that spans the entire market, through this bull run and the Great Recession. (9-0)

5 Sizzling Stocks Played Down by Hedge Funds in Q2

2018-08-16 zacks
Hedge funds are known for their capability to influence market movements. Their buy and sell decisions are diligently followed by institutional as well as retail investors as they provide clues on the future trajectory of the stock market. According to data from the latest HFR Global Hedge Fund Industry report, total hedge fund industry capital globally increased by $20.6 billion to a new record of $3. (38-2)

18 High-Growth Stocks With Massive Upside Ahead

2018-08-15 investorplace
This has been a market that favors high-growth stocks and not value plays. Obviously, the rising tide of the nine-year-plus bull market has lifted value boats as well. But clearly, the market of late has prioritized revenue growth over profit growth, to the point that many longtime value investors are in something close to despair. (108-6)

7 Internet Stocks to Buy on a 2018 Pullback

2018-08-15 investorplace
Will we get a summer pullback? Will it come in the fall? Possibly the fourth quarter? The bottom line is simple: We have no idea when a pullback will materialize. But we do know one thing. When it comes, we should have a list of internet stocks ready to buy. (60-1)